JHL’s AD-Bio Lab has recently been fitted with additional working space, including three working benches for new equipment purchases and expanded Analytical Capabilities.
Due to JHL’s need for additional capacity, the AD-Bio group has been working with Engineering every step of the way, from planning to construction completion. The new lab has added a 30% increase in space.
“We plan to introduce two systems in the near future to increase our analytical capability and efficiency,” said Toby Hong, Sr. Manager of Analytical Development-Bioassay. In Toby’s plan, a Fortebio system (BLI Technology) and a Meso Scale Device (MSD) will be purchased in the near future. The BLI Technology increases both the bandwidth and throughput for JHL’s bio-molecular interaction platforms in support of clone selection, process development and functional characterizations. The MSD system will expand the analytical portfolio to meet cytokine-, chemokine- and phosphorylation- related research needs.
“Protein analytical and functional characterizations are the foundation of biologics discovery and development,” emphasized Toby. Quality and Efficiency has always been the focal point for success at JHL and looking forward to 2020 and beyond, JHL will continue to operate under these values for both its own In-House Pipeline and their fast-growing Global CDMO services.
About JHL Biotech
JHL Biotech, Inc. is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, VMS Investment Group, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on continuing to provide the highest-quality CDMO services for our esteemed clients and also research and development of new protein-based therapies and biosimilars. JHL has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards and can produce biological products to be marketed globally. For more information, please visit www.jhlbiotech.com.